“…In addition, the mobility of point-of-care testing enables multidisciplinary management of patients and improves continuity of care. In Australia, practitioner-led point-of-care INR testing for the management of patients with AF has been trialled in general practices [271,272], outpatient clinics [273], aged-care facilities [274], and community pharmacies [275,276], as well as in conjunction with home-based medicine review services led by accredited pharmacists [277], across metropolitan or urban, [271,273,274,[277][278][279], rural [271,272,276,277], and remote [271,277] Resources and other considerations: In general, point-ofcare devices (and consumables such as testing strips) are currently relatively expensive to purchase (in the absence of Medicare rebates). Overall, they are generally cost effective in terms of optimising related health outcomes [280]; however, this depends on the overall model of care in which the devices are used [281].…”